Adagene (ADAG) Non-Current Assets (2019 - 2026)
Adagene (ADAG) posted quarterly Non-Current Assets of -$77375.1 billion for Q4 2025, up 11.85% year-over-year from -$69176.7 billion in Q4 2024, and down 6708557021.59% quarter-over-quarter from $1.2 million in Q2 2025.
Adagene (ADAG) Non-Current Assets (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Non-Current Assets for 7 consecutive years, with -$77375.1 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets rose 11.85% year-over-year to -$77375.1 billion; the TTM figure through Dec 2025 stood at -$165153.0 billion (up 50.54% YoY), while the FY2025 annual figure was -$77375.1 billion, up 11.85% from the prior year.
- Non-Current Assets declined to -$77375.1 billion in Q4 2025 per ADAG's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.6 million in Q4 2021 and bottomed at -$175012.9 billion in Q2 2022.
- Historically, Non-Current Assets has averaged -$73560.3 billion across 5 years, with a median of -$82576.5 billion in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 6596974610.4% — and 2024, when it jumped 100.0%.
- Adagene's Non-Current Assets stood at $3.6 million in 2021, then sank by 4197914475.81% to -$149315.3 billion in 2022, then grew by 24.02% to -$113443.6 billion in 2023, then grew by 22.62% to -$87777.9 billion in 2024, then grew by 11.85% to -$77375.1 billion in 2025.
- Business Quant data shows ADAG's Non-Current Assets at -$77375.1 billion in Q4 2025, $1.2 million in Q2 2025, and -$87777.9 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 1.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 Mn |
| Dec 31, 2025 | -77,375.09 Bn |
| Jun 30, 2025 | 1.15 Mn |
| Dec 31, 2024 | -87,777.92 Bn |
| Jun 30, 2024 | 1.98 Mn |
| Dec 31, 2023 | -113,443.61 Bn |
| Jun 30, 2023 | -132,678.62 Bn |
| Dec 31, 2022 | -149,315.28 Bn |
| Jun 30, 2022 | -175,012.85 Bn |
| Dec 31, 2021 | 3.56 Mn |
| Jun 30, 2021 | 2.65 Mn |
| Dec 31, 2020 | 5.17 Mn |
| Dec 31, 2019 | 1.97 Mn |